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Background
MVC is the first-in-class CCR5 antagonist approved for
use in treatment of CCR5-tropic (R5) HIV-1 infection;
however, there is limited experience with MVC in regi-
mens containing newer PIs and other new agents. This
open-label 96-week multi-center study evaluates MVC
in a variety of regimens to obtain additional safety and
efficacy data in TE patients with limited options due to
intolerance or resistance in Brazil.
Methods
Adult TE patients with R5 HIV-1 only (HIV-1 RNA
>1000 cp/mL) received MVC 150-600mg (based on con-
comitant ARV) twice daily, combined with optimized
background therapy (OBT). Every 12 weeks, safety para-
meters (primary endpoint), HIV RNA, and CD4 counts
were assessed; we report data at 48 weeks.
Results
Of treated 206 patients, 70% were male (mean age 43 yrs)
and 80% Caucasian; 2.9% and 5.8% were seropositive for
HBV or HCV infection, respectively. Median baseline
HIV-1 RNA and CD4 counts were 4.9 log10 copies/mL
and 185 cells/mm
3, respectively. OBT comprised PI
+NRTI (67%), PI+NRTI+NNRTI (7.8%), PI+NRTI+other
(14.6%), or other regimens (10.2%). The most frequently
used NRTIs were TDF (82%), 3TC (76%) and AZT (23%);
t h em o s tc o m m o nP I s( m o s tb o o s t e dw i t hR T V )w e r e
DRV (45%), LPV (41%) and ATV (15%); 16% received
RAL. OBTs contained ≤1 drug (1% of patients), 2 drugs
(7.3%), 3 drugs (24.3%), 4 drugs (35.4%), 5 drugs (23.8%),
or ≥6 drugs (8.2%). Sixty-five patients (31.6%) discontin-
ued; reasons included death (6 patients), adverse events
(5), insufficient clinical response (36), lost to follow-up
(4), or other (14). There were 238 treatment-related
adverse events in 103 patients; 16 treatment-related ser-
ious adverse events in 9 subjects; 10 category C events,
none treatment-related; and 2 of the 4 malignancies
(Hodgkin’s disease and intestinal T-cell lymphoma) were
considered treatment-related. The most common grade
3/4 lab test abnormalities were GGT elevation (11% of
patients), hyperbilirubinemia (11%) and serum amylase
elevation (6%). Median CD4 count increased persistently
through week 48 (Figure), with similar responses com-
paring quartiles of baseline CD4; the median increase
from baseline at week 48 was 164.5 cells/mm
3.H I V - 1
RNA decreases were maintained regardless of baseline
viral load; overall 41.1% of patients had HIV-1 RNA <400
copies/mL at week 48.
Conclusions
In highly TE patients, regimens combining MVC with
different agents from multiple classes were well toler-
a t e da n dp r o v i d e dm a r k e da n t i v i r a la n di m m u n o l o g i c
responses.
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